Denali Therapeutics Inc. (DNLI) Stock Price & Analysis
Denali Therapeutics Inc. (DNLI) rose 6.40% to USD 20.79 as of June 10, 2026 at 00:46 UTC, according to Nexqual real-time market data.
DNLI last closed at USD 19.54; the session ranged USD 19.45–20.94 on volume of 1,861,250 shares. Market capitalization is $3.30B, with a 52-week range of USD 12.58–23.77 (NMS). Source: Nexqual, June 10, 2026 at 00:46 UTC.
Key Statistics (as of June 10, 2026 at 00:46 UTC)
| Price | USD 20.79 |
|---|---|
| Change | ▲ 6.40% (up) |
| Previous Close | USD 19.54 |
| Open | USD 19.84 |
| Day Range | USD 19.45 – 20.94 |
| 52-Week Range | USD 12.58 – 23.77 |
| Volume | 1,861,250 shares |
| Market Cap | $3.30B |
| Exchange | NMS |
Technical Analysis (DNLI)
Nexqual's technical model rates DNLI "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 00:46 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.43 (neutral) |
| vs SMA50 | Above (USD 19.63) |
| MACD | 0.16 (positive) |
Analyst Ratings (DNLI)
Wall Street analysts rate DNLI "Strong Buy" based on 15 analysts, with a mean price target of USD 33.93 (range USD 20–42), per Nexqual as of June 10, 2026 at 00:46 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 33.93 |
| High Target | USD 42 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 18 / 1 / 0 |
Earnings (DNLI)
| Next Earnings Date | 2026-05-11 |
|---|---|
| EPS Estimate | USD -0.53 |
| Revenue Estimate | $2.17M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.69 vs est -0.71 ▲ beat |
| 2025-12-31 | USD -0.73 vs est -0.75 ▲ beat |
| 2025-09-30 | USD -0.74 vs est -0.76 ▲ beat |
| 2025-06-30 | USD -0.72 vs est -0.74 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financials & Fundamentals (DNLI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -49.59% |
| Debt / Equity | 4.32 |
| Current Ratio | 9.29 |
| Total Cash | $987.68M |
| Total Debt | $40.05M |
| Free Cash Flow | $-190.33M |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Financial Health Score (DNLI)
Nexqual rates Denali Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:46 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $988M cash vs $40M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$412M |
| Efficiency | Critical — ROE -50%, ROA -27.0% |
Ownership (DNLI)
| Insider Ownership | +9.14% |
|---|---|
| Institutional Ownership | +99.58% |
| Shares Outstanding | 158.71M |
| Float | 144.27M |
| Short % of Float | +9.33% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
Leadership (DNLI)
Denali Therapeutics Inc. is led by Ryan J. Watts (age 49), Co-Founder, President, CEO & Director, per Nexqual as of June 10, 2026 at 00:46 UTC.
| Co-Founder, President, CEO & Director | Ryan J. Watts (age 49) |
|---|---|
| Co-Founder, CFO, COO & Secretary | Alexander O. Schuth (age 52) |
| Chief Scientific Officer | Joe Lewcock |
Major Backers & Investors (DNLI)
Notable institutional backers of Denali Therapeutics Inc. include Baillie Gifford, T. Rowe Price, Temasek Holdings (Private) Ltd, according to Nexqual as of June 10, 2026 at 00:46 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baillie Gifford | 7.6% |
| T. Rowe Price | 6.84% |
| Temasek Holdings (Private) Ltd | 4.42% |
| FMR, LLC | 2.88% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.79% |
| Goldman Sachs | 2.78% |
| SmallCap World Fund Inc | 1.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.41% |
| BlackRock | 10.31% |
| State Street | 5.94% |
Source: Nexqual, June 10, 2026 at 00:46 UTC.
From Denali Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
- The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
- Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I).
- The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALEC | Alector, Inc. | USD 1.63 | ▼ 0.31% |
| ARVN | Arvinas, Inc. | USD 7.21 | ▼ 2.83% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 22.79 | ▲ 4.02% |
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:46 UTC. This page is informational and not investment advice.